New Treatment Approaches for Prostate Cancer Based on Peptide Analogues
Authors:
- Andrew V. SchallyASAndrew V. Schally
- Bob DjavanBDBob Djavan
- 1 May 2008
- journal article
- review article
- Published by Elsevier in European Urology
- Vol. 53 (5) , 890-900
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone AntagonistThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207The Prostate, 2006
- Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signallingEuropean Journal of Cancer, 2005
- Iterative Approach to the Discovery of Novel Degarelix Analogues: Substitutions at Positions 3, 7, and 8. Part IIJournal of Medicinal Chemistry, 2005
- Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancersThe Prostate, 2005
- Development of prostate cancer treatment: The good newsThe Prostate, 2004
- Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone–releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factorThe Prostate, 2002
- Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancersThe Prostate, 2000
- Future prospects in prostate cancerThe Prostate, 1999